Abstract
Refractory cancers exhibit profound tumor-induced immune suppression. IL-15, the homeostatic factor stimulating NK cells and T-cells, has shown little antitumor activity as a monotherapy and exhibits dose limiting toxicities. We hypothesized that simultaneous targeted delivery of IL-15 and cancer antigen directed NK cell killing would restore a patient’s endogenous NK cells from tumor induced immune suppression. We developed a novel Tri-Specific Killer Engager protein therapeutic, GTB-3550 TriKE™, comprised of two engagers targeting CD16 on NK cells, CD33 on myeloid malignancies, and an IL-15 linker.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
